Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Gravesâ disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
Related Questions
How will the sixâmonth offâtreatment remission data for batoclimab influence IMVT's valuation and shortâterm stock momentum?
What comparative advantages does batoclimab have over existing or pipeline therapies for uncontrolled Graves' disease, and how might this affect market share potential?
What are the projected timelines for regulatory approval, commercialization, and reimbursement for batoclimab, and how could these factors impact longâterm earnings forecasts?